Core Insights - Windtree Therapeutics, Inc. has entered into a License and Supply Agreement with Evofem Biosciences, Inc. to become the sourcing partner for PHEXXI, a hormone-free contraceptive vaginal gel, aiming to generate profitable revenue [1][2][3] - PHEXXI's annual revenues exceeded $19 million in 2024, with over 96,000 boxes sold, indicating strong market demand [1] - The partnership aims to reduce manufacturing costs for PHEXXI, enabling Evofem to expand into price-sensitive global markets [2][3] Company Strategy - Windtree's new corporate strategy, announced in January 2025, focuses on becoming a revenue-generating biotech by advancing innovative therapies and establishing partnerships [3][4] - The company plans to leverage its global manufacturing contacts to significantly lower the cost of goods for PHEXXI, enhancing profitability [2][3] Product and Market Potential - PHEXXI is positioned as a first-in-class product that empowers women by providing a non-hormonal contraceptive option [1][3] - The anticipated reduction in manufacturing costs is expected to facilitate Evofem's entry into new international markets, addressing the need for affordable contraceptive options [3]

Core Insights - Windtree Therapeutics, Inc. has received a Notice of Allowance from the United States Patent and Trademark Office for its patent application related to an intravenous formulation of istaroxime for treating acute heart failure [1] - The CEO of Windtree emphasizes the significant impact of acute heart failure on patients and healthcare systems, highlighting the need for innovative drug treatments [1] Company Overview - Windtree Therapeutics is a biotechnology company focused on developing innovative therapies for critical conditions, with a portfolio that includes istaroxime, which is in Phase 2 trials for acute heart failure and cardiogenic shock [3] - Istaroxime is a first-in-class dual-mechanism therapy that aims to enhance both systolic and diastolic cardiac function, showing promising results in improving cardiac function and blood pressure without adverse effects on heart rate [2][3]

Core Insights - Windtree Therapeutics, Inc. has filed a national phase patent application in India for istaroxime, aimed at preventing or reducing the risk of acute myocardial arrhythmia [1][2] - Istaroxime is a first-in-class dual-mechanism therapy designed to enhance both systolic and diastolic cardiac function, showing significant improvements in cardiac function and blood pressure in Phase 2 studies [2][3] Company Overview - Windtree Therapeutics focuses on developing innovative therapies for critical conditions, with a portfolio that includes istaroxime for acute heart failure and cardiogenic shock, as well as preclinical candidates for oncology applications [3] - The company employs a licensing business model and has established partnership out-licenses [3] Product Details - Istaroxime functions as a positive inotropic agent, increasing myocardial contractility and facilitating myocardial relaxation, which is crucial for patients with heart failure [2] - Clinical data indicates that intravenous infusion of istaroxime significantly improves cardiac function without increasing heart rate or the incidence of cardiac rhythm disturbances [2] Strategic Focus - The CEO of Windtree emphasizes the importance of India, with its population exceeding 1.4 billion, in the company's strategic intellectual property plan for istaroxime [2] - The company is preparing for Phase 3 readiness in cardiogenic shock, highlighting its commitment to securing intellectual property protection in key markets [2]

Core Points - Windtree Therapeutics, Inc. has announced a 1-for-50 reverse stock split approved by its board of directors and stockholders to comply with Nasdaq's minimum bid price requirement [1][2] - The reverse stock split will take effect on February 20, 2025, and trading on a reverse-adjusted basis will begin on February 21, 2025 [2] - Post-split, the number of outstanding shares will be reduced to approximately 700,000, with no fractional shares issued [4] Company Overview - Windtree Therapeutics is a biotechnology company focused on developing innovative therapies for critical conditions and diseases, including a Phase 2 candidate for acute heart failure [7] - The company has a licensing business model with existing partnership out-licenses [7]

Core Insights - Windtree Therapeutics, Inc. announced a positive presentation on istaroxime at the Technology and Heart Failure Therapeutics Conference, highlighting its potential in treating early cardiogenic shock [1][2] Company Overview - Windtree Therapeutics is a biotechnology company focused on innovative therapies for critical conditions, with a portfolio that includes istaroxime, which is in Phase 2 trials for acute heart failure and cardiogenic shock [5] Istaroxime Details - Istaroxime is a first-in-class dual-mechanism therapy designed to improve both systolic and diastolic cardiac function, enhancing myocardial contractility and facilitating myocardial relaxation [4] - The therapy has shown significant improvements in cardiac function and blood pressure in multiple Phase 2 studies without increasing heart rate or causing cardiac rhythm disturbances [4] Clinical Development - The company is prioritizing cardiogenic shock as an initial indication for istaroxime due to its unique profile and the positive outcomes from Phase 2 studies [3] - There is a substantial unmet need in treating early cardiogenic shock, as existing treatments often have undesirable side effects and poor outcomes [3]

Core Insights - Windtree Therapeutics, Inc. has announced the issuance of a patent in Japan for aPKCi inhibitors aimed at treating hedgehog pathway-dependent cancers, with the patent number 7603605 expiring in 2040 [1][2][3] Company Overview - Windtree Therapeutics is a biotechnology company focused on developing innovative therapies for critical conditions and diseases, with a portfolio that includes istaroxime for acute heart failure and preclinical aPKCi inhibitors for oncology applications [4] Product Development - The aPKCi inhibitor platform is a high-potency drug candidate with applications in treating various cancers, including basal cell carcinoma and small cell lung cancer, and includes both topical and oral formulations developed in collaboration with Cancer Research UK [2][3] - The company is also pursuing additional patent applications for crystalline forms of aPKCi inhibitors for cancer treatment [3] Strategic Direction - The issuance of the new patent is a significant part of the company's development strategy, with plans to expand its intellectual property portfolio in key global markets [3]

Core Insights - Windtree Therapeutics, Inc. has announced the issuance of a patent in Japan for its oncology aPKCi inhibitor, a novel drug candidate aimed at treating hedgehog pathway-dependent cancers, with the patent expiring in 2040 [1][3] Company Overview - Windtree Therapeutics is a biotechnology company focused on developing innovative therapies for critical conditions and diseases, with a portfolio that includes istaroxime for acute heart failure and preclinical aPKCi inhibitors for oncology applications [4] Product Development - The aPKCi inhibitor platform is a high-potency, specific drug candidate with applications in treating various cancers, including basal cell carcinoma and small cell lung cancer, and includes both topical and oral formulations developed in collaboration with Cancer Research UK [2][3] - The company is also pursuing additional intellectual property to expand its patent portfolio globally [3]

Core Insights - WINT Water Intelligence has formed a strategic partnership with Ferguson to enhance leak mitigation and water management solutions across the U.S. [1][2] - The collaboration aims to elevate industry standards in water management and leak detection, providing advanced technologies to Ferguson's distribution network [3][4] Company Overview - WINT Water Intelligence specializes in AI-based water management and leak-prevention solutions, focusing on reducing environmental impact and water waste [7][8] - Ferguson is the largest value-added distributor in the North American construction market, with sales of $29.6 billion in FY'24 and approximately 35,000 associates [9] Partnership Details - Ferguson will distribute WINT's advanced water management solutions, enhancing capabilities for construction companies [2][3] - The partnership is expected to improve water consumption monitoring, damage prevention, and sustainability efforts [3][4] Technological Impact - WINT's systems can reduce water consumption and associated carbon emissions by 20%-25% [4] - Construction sites using WINT technology report 73% fewer insurance claims and 90% less payout compared to sites without the technology [4] Clientele and Applications - WINT's solutions are utilized by major clients including Suffolk Construction, HP, and PepsiCo, among others [5] - The WINT platform offers comprehensive water monitoring, real-time leak detection, and advanced analytics powered by AI [6] Environmental Contributions - In 2023, WINT prevented over 900 water damage incidents, saving customers tens of millions of dollars and conserving 652 million gallons of water [7] - The company also prevented 22,000 metric tons of carbon emissions, contributing to sustainability goals [7]

Core Insights - Windtree Therapeutics, Inc. has appointed Leanne Kelly as an independent director and chair of the audit committee, enhancing the board's expertise [1][3] - Ms. Kelly brings over 20 years of experience in finance and management within the life sciences and technology sectors, having held various executive roles [2] - The company aims to become a revenue-generating biotech by acquiring small biotech firms with FDA-approved products, leveraging its equity for these acquisitions [3] Company Overview - Windtree Therapeutics focuses on developing innovative therapies for critical conditions, with a portfolio that includes istaroxime, a Phase II candidate for acute heart failure [3] - The company also has preclinical candidates targeting heart failure and oncology applications, alongside a licensing business model with existing partnerships [3]

WARRINGTON, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced it has launched a new corporate strategy to become a revenue generating biotech company through acquisitions of small companies and their FDA-approved products while the Company continues to progress its cardiovascular and oncology development ...